Transition of Blood Biomarkers During 24-Week Treatment With Lebrikizumab or Tralokinumab in Atopic Dermatitis: A Real-World Analysis Stratified by Prior Systemic Therapy
Restricted accessResearch articleFirst published online 2025
Transition of Blood Biomarkers During 24-Week Treatment With Lebrikizumab or Tralokinumab in Atopic Dermatitis: A Real-World Analysis Stratified by Prior Systemic Therapy
Abstract:Background: The transition of blood biomarkers has not been precisely examined in real-world treatments with anti-interleukin (IL)-13 antibodies for atopic dermatitis (AD).
Objective: To evaluate the transition of blood biomarkers during 24-week treatment with lebrikizumab or tralokinumab for patients with AD in real-world settings, stratified by the presence or absence of prior systemic therapy.
Methods: We conducted a retrospective study of Japanese patients with AD who received lebrikizumab (n = 148) or tralokinumab (n = 173). We measured serum immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), and total eosinophil count (TEC) at weeks 0, 4, 12, and 24 in systemic therapy-naïve or -experienced patients.
Results: IgE, TARC, and LDH decreased throughout the 24-week treatment with lebrikizumab or tralokinumab, while TEC transiently increased at week 4 or 12 in both systemic therapy-naïve and -experienced patients, and the magnitudes of decreasing IgE and TARC or increasing TEC were higher in the latter.
Conclusion: IgE, TARC, and LDH decreased during 24-week treatment with lebrikizumab or tralokinumab, while TEC transiently increased at week 4 or 12 in both systemic therapy- naïve and -experienced patients.
Get full access to this article
View all access options for this article.
References
1.
Chiesa FuxenchZC, BlockJK, BoguniewiczM, et al.Atopic dermatitis in America Study: A cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019; 139(3):583–590; doi: 10.1016/j.jid.2018.08.028
2.
HarropJ, ChinnS, VerlatoG, et al.Eczema, atopy and allergen exposure in adults: A population-based study. Clin Exp Allergy. 2007; 37(4):526–535; doi: 10.1111/j.1365-2222.2007.02679.x
HadiHA, TarmiziAI, KhalidKA, et al.The epidemiology and global burden of atopic dermatitis: A narrative review. Life (Basel). 2021; 11(9):936; doi: 10.3390/life11090936
DiepgenTL, OfenlochRF, BruzeM, et al.Prevalence of contact allergy in the general population in different European regions. Br J Dermatol. 2016; 174(2):319–329; doi: 10.1111/bjd.14167
7.
HondaT, KabashimaK. Reconciling innate and acquired immunity in atopic dermatitis. J Allergy Clin Immunol. 2020; 145(4):1136–1137; doi: 10.1016/j.jaci.2020.02.008
8.
HaginoT, SaekiH, KandaN. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2022; 49(11):1158–1167; doi: 10.1111/1346-8138.16549
9.
UchiyamaA, FujiwaraC, InoueY, et al.Possible suppressive effects of baricitinib on serum IL-22 levels in atopic dermatitis. J Dermatol Sci. 2022; 106(3):189–192; doi: 10.1016/j.jdermsci.2022.04.006
10.
KosakaK, UchiyamaA, IshikawaM, et al.Real-world effectiveness and safety of upadacitinib in Japanese patients with atopic dermatitis: A two-centre retrospective study. Eur J Dermatol. 2022; 32(6):800–802; doi: 10.1684/ejd.2022.4365
11.
NomuraT, SandilandsA, AkiyamaM, et al.Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J Allergy Clin Immunol. 2007; 119(2):434–440; doi: 10.1016/j.jaci.2006.12.646
12.
SilverbergJI. Atopic dermatitis in adults. Med Clin North Am. 2020; 104(1):157–176; doi: 10.1016/j.mcna.2019.08.009
13.
KamataM, TadaY. Optimal use of jak inhibitors and biologics for atopic dermatitis on the basis of the current evidence. JID Innov. 2023; 3(3):100195; doi: 10.1016/j.xjidi.2023.100195
14.
NakashimaC, YanagiharaS, OtsukaA. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors. Allergol Int. 2022; 71(1):40–46; doi: 10.1016/j.alit.2021.10.004
15.
BieberT. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020; 75(1):54–62; doi: 10.1111/all.13954
16.
Marbach-BreitrückE, KalledatA, HeydeckD, et al.Atopic patients show increased interleukin 4 plasma levels but the degree of elevation is not sufficient to upregulate interleukin-4-sensitive genes. Skin Pharmacol Physiol. 2019; 32(4):192–200; doi: 10.1159/000499431
17.
SzegediK, LutterR, ResPC, et al.Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin. J Eur Acad Dermatol Venereol. 2015; 29(11):2136–2144; doi: 10.1111/jdv.13160
18.
TubauC, PuigL. Therapeutic targeting of the IL-13 pathway in skin inflammation. Expert Rev Clin Immunol. 2021; 17(1):15–25; doi: 10.1080/1744666x.2020.1858802
19.
TsoiLC, RodriguezE, DegenhardtF, et al.Atopic dermatitis is an IL-13-Dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol. 2019; 139(7):1480–1489; doi: 10.1016/j.jid.2018.12.018
20.
SilverbergJI, Guttman-YasskyE, ThaçiD, et al.; ADvocate1 and ADvocate2 Investigators. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023; 388(12):1080–1091; doi: 10.1056/NEJMoa2206714
21.
BlauveltA, ThyssenJP, Guttman-YasskyE, et al.Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023; 188(6):740–748; doi: 10.1093/bjd/ljad022
22.
SimpsonEL, GooderhamM, WollenbergA, et al.; ADhere Investigators. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: A randomized clinical trial (ADhere). JAMA Dermatol. 2023; 159(2):182–191; doi: 10.1001/jamadermatol.2022.5534
23.
Stein GoldL, ThaçiD, ThyssenJP, et al.Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: An integrated analysis of eight clinical trials. Am J Clin Dermatol. 2023; 24(4):595–607; doi: 10.1007/s40257-023-00792-6
24.
HebertAA, FlohrC, HongHC, et al.Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials. J Dermatolog Treat. 2024; 35(1):2324833; doi: 10.1080/09546634.2024.2324833
25.
YosipovitchG, LioPA, RosmarinD, et al.Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: Two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2024; 190(2):289–291; doi: 10.1093/bjd/ljad435
26.
SimpsonEL, FlohrC, EichenfieldLF, et al.Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018; 78(5):863–871.e11; doi: 10.1016/j.jaad.2018.01.017
27.
TanakaA, IgawaK, TakahashiH, et al.Lebrikizumab combined with topical corticosteroids improves patient-reported outcomes in Japanese patients with moderate-to-severe atopic dermatitis. Acta Derm Venereol. 2024; 104:adv34375; doi: 10.2340/actadv.v104.34375
28.
SoungJ, StänderS, GutermuthJ, et al.Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials. J Dermatolog Treat. 2024; 35(1):2329240; doi: 10.1080/09546634.2024.2329240
29.
WollenbergA, BlauveltA, Guttman-YasskyE, et al.; ECZTRA 1 and ECZTRA 2 study investigators. Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021; 184(3):437–449; doi: 10.1111/bjd.19574
30.
SilverbergJI, TothD, BieberT, et al.; ECZTRA 3 study investigators. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: Results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021; 184(3):450–463; doi: 10.1111/bjd.19573
31.
PallerAS, FlohrC, CorkM, et al.Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: The phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol. 2023; 159(6):596–605; doi: 10.1001/jamadermatol.2023.0627
32.
SilverbergJI, AdamDN, ZirwasM, et al.Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic dermatitis over a 32-Week period: An ECZTRA 3 post hoc analysis. Am J Clin Dermatol. 2022; 23(4):547–559; doi: 10.1007/s40257-022-00702-2
33.
GutermuthJ, PinkAE, WormM, et al.Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: A placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol. 2022; 186(3):440–452; doi: 10.1111/bjd.20832
34.
SmithB, EngelP, WuJJ. Lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023; 388(24):2299; doi: 10.1056/NEJMc2304782
35.
LohTY, HsiaoJL, ShiVY. Therapeutic potential of lebrikizumab in the treatment of atopic dermatitis. J Asthma Allergy. 2020; 13:109–114; doi: 10.2147/jaa.S211032
36.
BernardoD, BieberT, TorresT. Lebrikizumab for the treatment of moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2023; 24(5):753–764; doi: 10.1007/s40257-023-00793-5
37.
LabibA, JuT, YosipovitchG. Managing atopic dermatitis with lebrikizumab—the evidence to date. Clin Cosmet Investig Dermatol. 2022; 15:1065–1072; doi: 10.2147/ccid.S295672
38.
UltschM, BeversJ, NakamuraG, et al.Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol. 2013; 425(8):1330–1339; doi: 10.1016/j.jmb.2013.01.024
39.
GonçalvesF, FreitasE, TorresT. Selective IL-13 inhibitors for the treatment of atopic dermatitis. Drugs Context. 2021; 10:2021; doi: 10.7573/dic.2021-1-7
40.
EwuluAR, PrajapatiS, FeldmanSR. The role of tralokinumab in the treatment of atopic dermatitis and future perspectives for adolescents. Immunotherapy. 2023; 15(16):1341–1349; doi: 10.2217/imt-2022-0307
41.
SimpsonEL, Guttman-YasskyE, EichenfieldLF, et al.Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition. Allergy. 2023; 78(11):2875–2891; doi: 10.1111/all.15811
42.
HaginoT, HamadaR, YoshidaM, et al.Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks. Front Immunol. 2024; 15:1365544; doi: 10.3389/fimmu.2024.1365544
43.
HaginoT, SaekiH, FujimotoE, et al.Identification of early and late responders to Anti-IL-13 antibody tralokinumab in atopic dermatitis: A real-world Japanese study. Dermatitis. 2024; doi: 10.1089/derm.2024.0460
44.
HaginoT, SaekiH, FujimotoE, et al.Predictive factors for poor responders to tralokinumab in moderate-to-severe atopic dermatitis: A real-world analysis. Dermatitis. 2025; doi: 10.1089/derm.2024.0515
45.
DekkersC, ZuithoffN, BakkerD, et al.Tralokinumab treatment in adult atopic dermatitis patients: 28-Week evaluation of clinical effectiveness, safety, serum proteins and total IgE levels. Allergy. 2025; 80(4):1060–1073; doi: 10.1111/all.16414
46.
HaginoT, SaekiH, FujimotoE, et al.A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: Systemic therapy-naive versus -experienced patients. J Am Acad Dermatol. 2025; 92(5):1049–1055; doi: 10.1016/j.jaad.2025.01.052
47.
SaekiH, OhyaY, FurutaJ, et al.; Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021, The Japanese Society of Allergology, The Japanese Dermatology Association. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021. Allergol Int. 2022; 71(4):448–458; doi: 10.1016/j.alit.2022.06.009
48.
WollenbergA, HowellMD, Guttman-YasskyE, et al.Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019; 143(1):135–141; doi: 10.1016/j.jaci.2018.05.029
49.
Guttman-YasskyE, KabashimaK, Staumont-SalleD, et al.Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy. 2024; 79(6):1560–1572; doi: 10.1111/all.16108
50.
HaginoT, OndaM, SaekiH, et al.Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan. Eur J Dermatol. 2024; 34(5):525–532; doi: 10.1684/ejd.2024.4750
51.
HaginoT, OndaM, SaekiH, et al.Effects of tralokinumab on clinical and laboratory indexes in atopic dermatitis: A 24-Week real-world study. Dermatitis. 2025; 36(3):235–243; doi: 10.1089/derm.2024.0323
52.
HaginoT, UchiyamaA, OndaM, et al.Real-World effectiveness and safety of lebrikizumab for moderate-to-severe atopic dermatitis: A 16-Week study in Japan. Dermatitis. 20 2025; doi: 10.1089/derm.2025.0004
53.
Guttman-YasskyE, BlauveltA, EichenfieldLF, et al.Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial. JAMA Dermatol. 2020; 156(4):411–420; doi: 10.1001/jamadermatol.2020.0079
54.
CaminatiM, OlivieriB, DamaA, et al.Dupilumab-induced hypereosinophilia: Review of the literature and algorithm proposal for clinical management. Expert Rev Respir Med. 2022; 16(7):713–721; doi: 10.1080/17476348.2022.2090342
55.
TosujiE, InabaY, MuraokaK, et al.The clinical significance of dupilumab-induced blood eosinophil elevation in Japanese patients with atopic dermatitis. Drug Discov Ther. 2022; 16(4):164–168; doi: 10.5582/ddt.2022.01046
56.
SimpsonEL, MerolaJF, SilverbergJI, et al.Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: Pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol. 2022; 187(6):888–899; doi: 10.1111/bjd.21867
57.
OlaguibelJM, SastreJ, RodríguezJM, et al.Eosinophilia induced by blocking the IL-4/IL-13 pathway: Potential mechanisms and clinical outcomes. J Investig Allergol Clin Immunol. 2022; 32(3):165–180; doi: 10.18176/jiaci.0823
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
